x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012391
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PARG protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PARG |
| UniProt No. | Q86W56 |
| Gene ID | 670 |
| Gene Description | Poly glycohydrolase is an enzyme that hydrolyzes poly formed by members of the PAR polymerase enzyme family. Poly -ribosylation is a post-translational modification that is catalyzed by PARP proteins. This modification involves polymerization of ADP-ribose from NAD+ to target proteins, such as histones and transcription factors, and plays a wide range of biological roles, including the response to DNA damage and transcriptional regulation. The mammalian PARG enzyme that catalyzes the removal of this modification exists as multiple isoforms. PARG isoforms 1-3 shuttle between the nucleus and cytoplasm and are responsible for most of the PARG activity. The smaller isoforms 4 and 5 reside in the cytoplasm. Research studies link altered PAR metabolism to inflammatory and autoimmune diseases, as well as neuronal degeneration. PARG inhibitors that increase PAR levels may sensitize cells to cancer treatments and may help in the development of cancer therapies. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
